Elsevier launches TargetInsights support tool

Friday, February 10, 2012 01:59 PM

Elsevier, a provider of scientific, technical and medical information products and services, has launched TargetInsights, an online decision support tool.

The tool enables scientists to search, monitor and stay up-to-date with the latest biological insights reported in scientific literature. It provides extensive information coverage and data contextualization, supporting users to identify, prioritize and validate biological targets faster and with less risk.

TargetInsights was designed to overcome information challenges during the discovery process of target identification and validation, when scientists need to support ideation and findings with extensive reviews of scientific literature. The tool enables full text entity and relationship searching of over 5,000 international biomedical journals covering over 800,000 journal articles and conference abstracts per year.

Recognizing the need for information immediacy among these users, articles are indexed and appear in TargetInsights 10 days after publication. To support search accuracy, tools are provided to hone and visualize index term relationship searching.

"We have designed this online support tool to operate at what is widely regarded as a mission-critical phase of drug development," said Jabe Wilson, senior product manager at Elsevier. "Many failures in drug development can be attributed to improper target selection. For scientists focusing on a biological target, it is imperative to be able to search and screen crucial information. Incomplete or inaccurate information can result in unnecessary experiments and poor business decisions."

Share:          
CWWeekly

May 21

Parexel consultant testifies on FDA biosimilars guidance

Global Telecom Testing checks ex-U.S. toll-free phone lines for multinational clinical trials

To read the full articles for this issue of CWWeekly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

CWWeekly

May

Newer sites most optimistic about the future
Investigative sites of all sizes, from part-time physician-run sites to large dedicated research centers, report a rebound in operating conditions, according to a new CenterWatch analysis, yet sites from each subgroup indicate they have concerns…

Risk-based monitoring slow to catch on with industry
It's estimated that the cost of physically sending monitors to all investigative sites at regular intervals, a model the industry itself developed and has adhered to for about a decade, eats up one-third to one-half of…

Eye On Millennium
Millennium, The Takeda Oncology Company, discovers and develops novel treatments applying world-class recombinant technology to a wide variety of oncology disease targets…

To read the full articles for this issue of The CenterWatch Monthly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

JobWatch centerwatch.com/jobwatch

Featured Jobs